Debt-to-equity of Kymera Therapeutics, Inc. from 30 Jun 2021 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kymera Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 31 Dec 2025.
  • Kymera Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 14%, a 24% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Kymera Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 14% -4.4% -24% 31 Dec 2025
Q3 2025 17% -6.5% -28% 30 Sep 2025
Q2 2025 17% -13% -43% 30 Jun 2025
Q1 2025 17% -16% -47% 31 Mar 2025
Q4 2024 19% -19% -51% 31 Dec 2024
Q3 2024 23% -8.7% -27% 30 Sep 2024
Q2 2024 29% +0.82% +2.9% 30 Jun 2024
Q1 2024 33% +5.4% +20% 31 Mar 2024
Q4 2023 38% +10% +38% 31 Dec 2023
Q3 2023 32% +2.3% +7.8% 30 Sep 2023
Q2 2023 28% -3.7% -12% 30 Jun 2023
Q1 2023 28% -10% -27% 31 Mar 2023
Q4 2022 27% -18% -40% 31 Dec 2022
Q3 2022 30% -26% -47% 30 Sep 2022
Q2 2022 32% -38% -55% 30 Jun 2022
Q1 2022 38% 31 Mar 2022
Q4 2021 45% 31 Dec 2021
Q3 2021 56% 30 Sep 2021
Q2 2021 70% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.